Treatment guidelines for hyperglycaemia in type 2 diabetes patients with stable chronic heart failure or ischemic cardiomyopathy without heart failure;Tratamiento hipoglucemiante en pacientes con diabetes mellitus tipo 2 con insuficiencia cardiaca estable o cardiopatía isquémica sin insuficiencia cardiaca

Medicina Clinica

Volumn 134, Issue 13, 2010, Pages 596-599

  Alonso García, Ángeles ^a   García Soidán, Francisco J ^b   Lisbona Gil, Arturo ^c  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b Centro de Salud de Porrino   (Spain)

^c HOSPITAL CENTRAL DE LA DEFENSA GÓMEZ ULLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SITAGLIPTIN;

ARTICLE; COMORBIDITY; DRUG CONTRAINDICATION; HEART FAILURE; HUMAN; HYPERGLYCEMIA; ISCHEMIC HEART DISEASE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE;

ACUTE CORONARY SYNDROME; ALGORITHMS; CONSENSUS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FORECASTING; HEART FAILURE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; MYOCARDIAL ISCHEMIA; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; SPAIN; THIAZOLIDINEDIONES;

EID: 77951122371     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2010.01.028     Document Type: Article

References (31)

1. Buse J.B., Ginsberg H.N., Bakris G.L., Clark N.G., Costa F., Eckel R., et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association. Circulation 115 (2007) 114-126
2. Turner R.C., Millns H., Neil H.A., Stratton I.M., Manley S.E., Matthews D.R., et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316 (1998) 823-828
3. Wei M., Gaskill S.P., Haffner S.M., and Stern M.P. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diab Care 21 (1998) 1167-1172
4. Haffner S.M. Coronary heart disease in patients with diabetes. N Engl J Med 342 (2000) 1040-1042
5. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 352 (1998) 837-853
7. DCCT/EDIC Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005) 2643-2653
8. Holman R.R., Paul S.K., Bethel A., Matthews D.R., and Neil A.W. 10-year follow-up of intensive glucose control in type 2 ciabetes. N Engl J Med 359 (2008) 1577-1589
9. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008) 2545-2559
10. ADVANCE Collaborative Group. Intensive blood glucose and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008) 2560-2572
11. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P., et al., VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2009) 129-139
12. Turnbull F.M., Abraira C., Anderson R.J., Byington R.P., Chalmers J.P., Duckworth W.C., et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52 (2009) 2288-2298
13. Ray K.K., Seshasai S.R., Wijesuriya S., Sivakumaran R., Nethercott S., Preiss D., et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: A meta-analysis of randomised controlled trials. Lancet 373 (2009) 1765-1772
14. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32 (2009) 193-203
15. McGuire D.K., and Inzucchi S.E. New drugs for the treatment of diabetes mellitus: Part I: Thiazolidinediones and their evolving cardiovascular implications. Circulation 117 (2008) 440-449
16. Inzucchi S.E., and McGuire D.K. New drugs for the treatment of diabetes: Part II: Incretin-based therapy and beyond. Circulation 117 (2008) 574-584
17. Fisman E.Z., and Tenenbaum A. A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. Cardiovasc Diabetol 8 (2009) 38
18. Eurich D.T., McAlister F.A., Blackburn D.F., Majumdar S.R., Tsuyuki R.T., Varney J., et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: Systematic review. BMJ 335 (2007) 497
19. Aguilar D. Management of type 2 diabetes in patients with heart failure. Curr Treat Options Cardiovasc Med 10 (2008) 465-475
20. Schramm TK, Gislason GH, Hospet R, Rasmussen S, Jørgensen CH, Folke F, et al. Abstract 3226: Differences in risk of death according to type of oral glucose-lowering therapy in patients with diabetes: A nationwide study. [resumen]. Circulation. 2008;118:1117.
21. Holstein A., and Stumvoll M. Contraindications can damage your health - is metformin a case in point?. Diabetologia 48 (2005) 2454-2459
22. Inzucchi S.E., Masoudi F.A., and McGuire D.K. Metformin therapy in patients with type 2 diabetes complicated by heart failure. Am Heart J 154 (2007) e45
23. Khurana R., and Malik I.S. Metformin: Not the bad guy. Heart 96 (2010) 99-102
24. Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology; ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive. Care Medicine (ESICM). Eur Heart J 29 (2008) 2388-2442
25. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al., PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 366 (2005) 1279-1289
26. Gerstein H.C., Yusuf S., Bosch J., Pogue J., Sheridan P., Dinccag N., et al. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet 368 (2006) 1096-1105
27. Singh S., Loke Y.K., and Furberg C.D. Thiazolidinediones and heart failure: A teleo-analysis. Diabetes Care 30 (2007) 2148-2153
28. Amori R.E., Lau J., and Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA 298 (2007) 194-206
29. De Block C.E., and Van Gaal L.F. GLP-1 receptor agonists for type 2 diabetes. Lancet 374 (2009) 4-6
30. Home P.D., Pocock S.J., Beck-Nielsen H., Curtis P.S., Gomis R., Hanefeld M., et al., RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial. Lancet 373 (2009) 2125-2135
31. The BARI 2D study group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 360 (2009) 2503-2515